8-K: ProMIS Neurosciences Advances PMN310 to Final Phase 1b AD Trial Cohort

ProMIS Neurosciences' lead Alzheimer's therapeutic candidate, PMN310, has received unanimous DSMB approval to proceed to the third and final dose escalation cohort in its Phase 1b clinical trial, with no amyloid-related imaging abnormalities observed to date.

Summary

• The independent Data and Safety Monitoring Board (DSMB) for the PRECISE-AD Phase 1b clinical trial unanimously recommended advancing PMN310 to the third and final dose escalation cohort.
• PMN310 is ProMIS Neurosciences' lead therapeutic candidate for the treatment of Alzheimer's disease.
• Cohort 2 of the trial has been fully enrolled, and enrollment of patients into Cohort 3 is now underway.
• No cases of amyloid-related imaging abnormalities (ARIA) have been observed to date across all cohorts.
• The trial remains on track to deliver 6-month interim data in the second quarter of 2026 and final 12-month top-line results in the fourth quarter of 2026.
• PMN310 is a humanized IgG1 antibody designed to selectively target toxic amyloid-beta oligomers (AOs) while avoiding plaque, aiming to reduce ARIA liability.
• The final dose level for Cohort 3 will be 20 mg/kg, an increase from the 10 mg/kg dose used in Cohort 2.
• The PRECISE-AD trial is designed to enroll 128 patients.

Sentiment

Score: 8

Explanation: The unanimous DSMB recommendation to advance to the final dose cohort, coupled with a clean safety profile (no ARIA observed) and the trial remaining on schedule, represents a significant positive milestone for PMN310. The differentiated mechanism of action and recent Fast Track designation further bolster confidence. While still in early-stage clinical development, these are strong indicators of progress and de-risking.

Positives

• Unanimous recommendation from the independent DSMB to proceed to the third and final dose escalation cohort for PMN310.
• No cases of amyloid-related imaging abnormalities (ARIA) have been observed to date, indicating a favorable safety profile.
• The PRECISE-AD trial remains on track for its planned 6-month interim data readout in Q2 2026 and final 12-month top-line results in Q4 2026.
• PMN310's differentiated mechanism of action targets toxic oligomers, potentially reducing off-target effects and safety concerns associated with plaque-targeting therapies.
• PMN310 recently received FDA Fast Track designation in July 2025.
• Cohort 2 is fully enrolled, and enrollment for Cohort 3 is actively underway.

Risks

• Clinical results or early results from the trial may not be indicative of future results.
• The company's ability to fund its operations and continue as a going concern is a risk.
• The company has an accumulated deficit and expects continued losses.
• Future financial results are subject to various uncertainties.
• General risks discussed in the Company's most recently filed Annual Report on Form 10-K for the year ended December 31, 2024, and in its subsequent filings with the United States Securities and Exchange Commission.

Future Outlook

The company expects to deliver 6-month interim data from the PRECISE-AD trial in the second quarter of 2026 and final 12-month top-line results in the fourth quarter of 2026. Management anticipates PMN310's selective targeting of toxic oligomers to offer an improved efficacy and safety profile, potentially meeting a critical unmet need in Alzheimer's disease by reducing off-target effects and safety concerns like ARIA.

Management Comments

• "The DSMBs recommendation to proceed with the planned escalation to the final dose cohort underscores the steady progress of our Phase 1b program and keeps us firmly on track toward our planned interim and top-line data readouts in 2026." Neil Warma, President and CEO.
• "Together with the recent FDA Fast Track designation for PMN310, this achievement highlights the momentum we are building as we advance through clinical development." Neil Warma, President and CEO.
• "Unlike therapies directed at amyloid plaque, which continue to be associated with safety concerns, PMN310 is engineered to avoid plaque and precisely target only toxic oligomers, the amyloid species most closely linked to neuronal damage and disease progression." Neil Warma, President and CEO.
• "The favorable safety profile observed to date highlights this differentiated strategy and reinforces the potential of PMN310 to meet a critical unmet need in Alzheimers disease." Neil Warma, President and CEO.
• "The safety profile observed with PMN310 to date is encouraging and consistent with its design as a highly selective antibody targeting toxic oligomers." Larry Altstiel, M.D., Ph.D., Chief Medical Officer.
• "By potentially avoiding plaque and monomer binding, we believe PMN310 may reduce off-target effects and focus therapeutic activity on the molecular species most implicated in disease progression." Larry Altstiel, M.D., Ph.D., Chief Medical Officer.
• "As we enter the final cohort, we look forward to assessing a comprehensive biomarker panel, including pTau217, pTau243, neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), Abeta42/40 ratios and synaptic integrity markers such as SNAP25 and neurogranin, to provide critical insights into target engagement, neuronal injury, and potential disease-modifying effects." Larry Altstiel, M.D., Ph.D., Chief Medical Officer.

Industry Context

ProMIS Neurosciences is positioning PMN310 as a next-generation therapy for Alzheimer's disease, distinguishing itself by selectively targeting toxic amyloid-beta oligomers while aiming to avoid amyloid plaque. This approach is designed to mitigate safety concerns, such as amyloid-related imaging abnormalities (ARIA), which are commonly associated with other amyloid-directed therapies that target plaque. The recent FDA Fast Track designation further underscores the potential significance and urgency of PMN310 in the competitive and rapidly evolving Alzheimer's drug development landscape, where safety and efficacy differentiation are paramount.

Comparison to Industry Standards

• PMN310's observed safety profile, with no cases of amyloid-related imaging abnormalities (ARIA) to date, contrasts favorably with other amyloid-directed therapies that target amyloid plaque, which have been associated with ARIA as a significant side effect.
• The company explicitly states that PMN310 is engineered to avoid plaque and precisely target only toxic oligomers, differentiating its mechanism from broader amyloid-targeting antibodies like aducanumab (Aduhelm) or lecanemab (Leqembi) that bind to amyloid plaques.
• PMN310's design to potentially avoid plaque and monomer binding aims to reduce off-target effects, which could offer an improved safety and efficacy profile compared to other amyloid-targeting antibodies in development or on the market.

Stakeholder Impact

• Shareholders: The positive clinical trial progression and favorable safety profile could increase investor confidence and potentially lead to an appreciation in share price.
• Patients with Alzheimer's Disease: PMN310's potential to offer a safer and more effective treatment option, particularly by avoiding ARIA, could significantly improve patient outcomes and quality of life if successful.
• Employees: Continued positive clinical development provides job security and motivation within the company.
• Regulatory Authorities: The positive DSMB recommendation and Fast Track designation indicate adherence to regulatory standards and potential for expedited review pathways.

Next Steps

• Continue enrollment and dosing of patients into Cohort 3 (final dose level) of the PRECISE-AD trial.
• Deliver 6-month interim data from the PRECISE-AD trial in the second quarter of 2026.
• Deliver final 12-month top-line results from the PRECISE-AD trial in the fourth quarter of 2026.
• Neil Warma, President and CEO, will discuss clinical progress and other corporate updates at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025.

Key Dates

Recommendation

The unanimous DSMB approval to advance PMN310 to the final dose escalation cohort, critically with no observed amyloid-related imaging abnormalities (ARIA), is a highly significant de-risking event for ProMIS Neurosciences. This positive safety signal, combined with the recent FDA Fast Track designation and the trial remaining on schedule for key data readouts in 2026, strongly validates the company's differentiated approach to targeting toxic amyloid-beta oligomers. Given the substantial unmet medical need in Alzheimer's disease and the potential for PMN310 to offer a safer and potentially more effective alternative to existing plaque-targeting therapies, this update positions the company for significant future value creation. The market is likely to react very positively to this news, making it a strong buy for investors seeking exposure to innovative Alzheimer's therapeutics.

Keywords

Alzheimer's disease, PMN310, clinical trial, Phase 1b, DSMB, neurodegenerative, amyloid-beta oligomers, biotechnology, drug development, PRECISE-AD, ARIA, Fast Track designation, toxic oligomers